arginine vasopressin receptor 2 ; Homo sapiens






419 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 1330628 Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries. Eur J Pharmacol 1992 Oct 20 1
2 1333280 The mobile receptor hypothesis revisited: a mechanistic role for hormone receptor lateral mobility in signal transduction. Biochim Biophys Acta 1992 Dec 11 1
3 1672792 Autosomal recessive inheritance of vasopressin-resistant diabetes insipidus. Am J Med Genet 1991 Jan 1
4 2168411 Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors. J Biol Chem 1990 Sep 15 2
5 2960813 Potent vasopressin antagonists modified at the carboxy-terminal tripeptide tail. J Med Chem 1987 Dec 2
6 2986401 Urinary adenosine 3',5'-monophosphate (cAMP) response to antidiuretic hormone in diabetes insipidus (DI): comparison between congenital nephrogenic DI type 1 and 2, and vasopressin sensitive DI. Acta Endocrinol (Copenh) 1985 Apr 2
7 7575330 Diabetes insipidus. Baillieres Clin Endocrinol Metab 1995 Jul 1
8 7640759 [Hereditary nephrogenic diabetes insipidus]. Arch Pediatr 1995 Jun 1
9 7750456 Drosophila insulin receptor: lectin-binding properties and a role for oxidation-reduction of receptor thiols in activation. Endocrinology 1995 Jun 8
10 7868891 Recombination potential of the human DIR elements. J Immunol 1995 Mar 1 2
11 7939338 [Congenital nephrogenic diabetes insipidus]. Rev Prat 1994 May 1 1
12 7977526 Indomethacin and arginine vasopressin interaction in the fetal kidney: a mechanism of oliguria. Am J Obstet Gynecol 1994 Nov 4
13 8076430 Interaction between epidermal growth factor and arginine vasopressin in renal medullary membranes. Clin Exp Pharmacol Physiol 1994 Mar 3
14 8140421 Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994 Apr 1 1
15 8251321 Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus. Pediatr Nephrol 1993 Oct 2
16 8351566 Lithium-induced nephrogenic diabetes insipidus treated with indomethacin. South Med J 1993 Aug 6
17 8401502 A Null mutation in the vasopressin V2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus in the Hopewell kindred. Hum Mol Genet 1993 Aug 1
18 8573100 Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem J 1996 Jan 15 1
19 8628319 The Drosophila insulin receptor activates multiple signaling pathways but requires insulin receptor substrate proteins for DNA synthesis. Mol Cell Biol 1996 May 2
20 8739289 Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use. Am J Nephrol 1996 3
21 8784453 Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds. J Med Chem 1996 Aug 30 1
22 8808225 Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 1995 Dec 2
23 8855130 [Diuretics]. Nihon Jinzo Gakkai Shi 1996 Jan 1
24 9224808 Palmitoylation of the V2 vasopressin receptor. Mol Pharmacol 1997 Jul 3
25 9482866 A serine cluster prevents recycling of the V2 vasopressin receptor. Proc Natl Acad Sci U S A 1998 Mar 3 3
26 9711877 V2 vasopressin receptor dysfunction in nephrogenic diabetes insipidus caused by different molecular mechanisms. Hum Mutat 1998 1
27 9730911 A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. Mol Pharmacol 1998 Sep 5
28 9756088 Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Proc Assoc Am Physicians 1998 Sep-Oct 1
29 9831428 Nephrogenic diabetes insipidus. Am J Med 1998 Nov 1
30 9834976 Pathogenesis of sodium and water retention in cardiac failure. Ren Fail 1998 Nov 3
31 10026835 VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998 1
32 10027817 Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. Circulation 1999 Feb 23 2
33 10071770 Molecular dynamics of a vasopressin V2 receptor in a phospholipid bilayer membrane. J Recept Signal Transduct Res 1999 Jan-Jul 1
34 10362843 O-Glycosylation of the V2 vasopressin receptor. Glycobiology 1999 Jul 10
35 10598313 [Between efficiency and toxicity: the case of a patient improved by lithium who developed iatrogenic nephropathy]. Encephale 1999 Sep-Oct 1
36 10638391 Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999 Nov 1
37 10648632 Molecular and conformational features of a transport-relevant domain in the C-terminal tail of the vasopressin V(2) receptor. Mol Pharmacol 2000 Feb 2
38 10648821 The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues. FEBS Lett 2000 Jan 21 2
39 10802073 Corrigendum to: the role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues. FEBS Lett 2000 May 4 1
40 10880054 Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000 Jul 4
41 11012895 Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int 2000 Oct 1
42 11145096 [From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus]. Ned Tijdschr Geneeskd 2000 Dec 9 1
43 11374981 Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist. J Org Chem 2001 Jun 1 1
44 11433224 Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001 Jul 2
45 11607038 An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev 2001 Fall 1
46 11779113 Engineering a V(2) vasopressin receptor agonist- and regulator of G-protein-signaling-sensitive G protein. Anal Biochem 2002 Jan 15 1
47 12414899 Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. J Clin Endocrinol Metab 2002 Nov 1
48 12473133 Development of a DNA-based genotyping method for the Diego blood group system. Transfusion 2002 Dec 4
49 12503936 Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus. Ann Pharmacother 2003 Jan 5
50 12639574 Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists. Bioorg Med Chem Lett 2003 Feb 24 1